| Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: late-stage assessment | HTE31 | | |
| Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments | TA1091 | | |
| Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma | TA1090 | | |
| Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over | TA1088 | | |
| Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal) | TA1089 | | |
| Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence | TA1086 | | |
| Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen | TA1087 | | |
| Overweight and obesity management | QS212 | | |
| Single-step scaffold insertion for repairing symptomatic chondral knee defects | IPG793 | | |
| Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over | TA1085 | | |
| Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessment | HTE30 | | |
| Cenobamate for treating focal onset seizures in epilepsy | TA753 | | |
| Cardiovascular risk assessment and lipid modification | QS100 | | |
| Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal) | TA1084 | | |
| Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal) | TA1082 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal) | TA1083 | | |
| Fruquintinib for previously treated metastatic colorectal cancer | TA1079 | | |
| One-piece closed bags for colostomies: late-stage assessment | HTE29 | | |
| Pulsed-field ablation for atrial fibrillation | IPG806 | | |
| Mirikizumab for previously treated moderately to severely active Crohn's disease | TA1080 | | |
| Zanubrutinib for treating relapsed or refractory mantle cell lymphoma | TA1081 | | |
| Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessment | HTE28 | | |
| Dapagliflozin for treating chronic kidney disease | TA1075 | | |
| Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal) | TA1076 | | |
| Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over | TA1077 | | |
| Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal) | TA1078 | | |
| Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation | IPG805 | | |
| Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies | TA1073 | | |
| Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment | HTE27 | | |
| Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA1071 | | |
| Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA1072 | | |
| Spesolimab for treating generalised pustular psoriasis flares | TA1070 | | |
| Targeted muscle reinnervation for managing limb amputation pain | IPG804 | | |
| Caesarean birth | NG192 | | |
| Linzagolix for treating symptoms of endometriosis | TA1067 | | |
| Efgartigimod for treating antibody-positive generalised myasthenia gravis | TA1069 | | |
| Headaches in over 12s: diagnosis and management | CG150 | | |
| Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease | IPG803 | | |
| Somapacitan for treating growth hormone deficiency in people 3 to 17 years | TA1066 | | |
| Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) | TA1068 | | |
| Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA1065 | | |
| Abortion care | NG140 | | |
| Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA1064 | | |
| Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment | TA1063 | | |
| Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor | TA1062 | | |
| Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer | TA1060 | | |
| Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment | HTE25 | | |
| Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma | TA1059 | | |
| Drug-eluting stents for treating coronary artery disease: late-stage assessment | HTE26 | | |
| Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal) | TA1061 | | |